Environmental Factors, Genes and Human Cancers

Parsa, Naser

Environmental Factors, Genes and Human Cancers

Document Type : Promotion Article

Author

Naser Parsa

National Institutes of Health, Ministry of Health, USA

Abstract

In the past 50 years, researchers have made a remarkable progress in identifying the biological (bacteria, viruses), biochemical (chemical compounds) and biophysical (ionizing radiation) cause of human cancers. The term "Cancer” refers to 277 forms of cancer diseases. Scientists have discovered the process of cancer formation from a consequence of accumulating multiple mutations in human genome. These genetic disruptions would eventually change the normal pathway of cellular proliferations and differentiation. These genetic alterations are frequently indicative of poor prognosis for most human cancers. Both nonhereditary and hereditary cancers are caused by genetic accidents that change the cellular growth control systems. Genes associated with human cancer formation include four classes of genes: 1. Oncogenes, 2. Tumor suppressor genes, 3. DNA repairing genes. 4. Apoptotic genes. Over activated oncogenes which cause cellular proliferation. In contrast, inactivated tumor suppressor genes lose their inhibitory effect which is crucial to prevent inappropriate growth. DNA repairing proteins fix the damage and apoptotic proteins cause the precancer cell to commit suicide. We have over millions genes in each somatic cell of our body. After sequencing all human genome in 2003, we noticed that Only 23,500 genes are active which encode over 400,000 proteins needed for physiological functions. 99.9% of genome is identical in all humans worldwide. Only 0.1% of the whole genome differ which cause the genetic variations. Up to 93% of all human cancers are non-hereditary and the remaining 7% are hereditary. A wealth of information indicating the potential use of molecular techniques for cancer screening, prognosis and monitoring of the efficacy of anticancer therapies. In recent years, molecular genetics have greatly increased our understanding of the basic mechanisms in cancer development. The essential outcome of these molecular studies is that cancer can be considered as genetic disease of the cells.

Keywords

20.1001.1.2008935.1390.02.1.2.8

References

[1]. Scotto J, Fears TR, Fraumeni Jr(1996) “Solar Radiation. In: Schottenfeld D, Fraumeni JF Jr, eds: Cancer Epidemiology and Prevention. 2nd ed. New York, NY: Oxford University Press. PP 355-72.
[2]. Vogelstein B, Kinzler KW(2004).” Cancer Genes and the Pathways they Control. Nat Med 2004; Vol.10, No.8,pp. 789-99.
[3]. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL(1988).” Genetic Alterations during Colotectal- Tumor Development. N Engl J Med. No. 319, pp. 525-532.
[4]. Hanahan D, Weinberg RA(2000).” The Hallmarks of Cancer Cell. No. 100, pp. 57-70.
[5]. Hanahan D, Weinberg RA(2000).” The Hallmarks of Cancer Cell”. Vol.100,No.1, pp.57-70.
[6]. Sonnenschein C, Soto AM( 2008).” Theories of Carcinogenesis: an Emerging perspective. Semi Cancer Biol. Vol. 18No.5, pp. 372-7.
[7]. Pakin DM(2006).” The Global Health Burden of Infection-Associated Cancers in the years 2002. Int J Cancer. Vol.118, No.12, pp. 3030-44.
[8]. National RC. Committee to Assess Health Risks from Exposure to Low Levels of Inoizing Radiation(2011).” BEIR VII Phase 2. Washington.
[9]. Fazel R, Krumholz HM, Wang R, et al. (2009).” Exposure to Low-Dose Ionizing Radiation from Medical Imaging Procedures. N Engl J Med. 2009, Vol.361, No.9. 849-57.
[10]. William WN Jr, Heymach JV, Kim ES, et al (2009).” Molecular Targets for Cancer Chemoprevention. Nat Rev Drug Discov. Vol.8, No.3,pp. 213-25.
[11]. Seto M, Honma K, Nakagawa M. (2010). “Diversity of Genome Profiles in Malignant Lymphoma. Cancer Science.No.101, pp. 573-578.
[12]. Staal SP. Huebner K, Croce CM, Parsa N, et al(1988). “ The Akt-1 Proto Oncogene Maps to Human Chromosome 14, Band q32, a Site of Chromosome Rearrangement in some Hematopoietic Neoplasma. Journal of Genomics. No.2, pp. 96-98.
[13]. Park M, Testa JR, Blair DG, Parsa N, et al. ( 1988).” Two Rearranged Met Alleles on Chromosome 7 to other Markers Tightly Linked to Cystic Fibrosis. Proceeding of the National Academy of Sciences, USA. No.85pp. 2667-2671.
[14]. Offit K, Parsa N, Jhanwar SC, Filippa DA, et al.( 1992).” Denotes a Subset of Low to Intermediate Grade B-cell Non-Hodgkin΄s Lymphoma”. Journal of the American Society of Hematology(Blood). No. 80, pp.45-60.
[15]. Parsa N, Gaidano G, Mukherjee, AB, Hauptschein RS, et al.( 1994). “Cytogenetic and Molecular Analysis of 6q Deletions in Burkitt΄s Lymphoma Cell Lines”. Journal of Genes, Chromosomes & Cancer. No. 9, pp. 13-18.
[16]. Papanicolaou, GJ, Parsa N, Meltzer PS, Trent JM(1997). “Assignments of Interferon Gama Receptor(INFGR1) to Human Chromosome Bands” 6q24.1 →q24.2 by Fluorescent In Situ hybridization”. Journal of Cytogenetics and Cell Genetics. 1997; 76: 181-182.
[17]. Cigudosa JC, Parsa N, Louie DC, Filippa DA, Mitlema F, Chaganti RSK( 1999). Cytogenetic Analysis of 363 Consecutively Ascertained Diffuse Large B-cell Lymphomas. Journal of Genes, chromosoma & Cancer”. No. 25, pp.123-133.
[18]. Shtivelman E, Lifshitz B, Gale RP, Canaani E.(1985).” Fused Transcript of abl and bcr Genes in Chronic Myelogenous Leukemia. Nature No.315, pp.550-554.
[19].Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N Engl J Med 2001;344:1031-1037.
[20]. Joensuu H, Dimitrijevic S. Tyrosine Kinase Inhibitor Imatinib (STI571) As An Anticancer Agent for Solid Tumours. Ann Med 2001;33:451-455.
[21]. King CR, Kraus MH, Aaronson SA.(1985)” Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma”. Science ;229: 974-976.
[22]. Heinrich MC, Blanke CD, Druker BJ, Corless CL.(2002). Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies. J Clin Oncol 2002;20:1692-1703.
[23]. Wei, Qingyi; Lei Li, David Chen (2007). DNA Repair, Genetic Instability, and Cancer. World Scientific. ISBN 981-270-014-5.
[24]. Hogervorst FB. et al. (2003). “Large Genomic Deletions and Duplications in the BRCA1 Gene Identified by a Novel Quantitative Method”. Cancer Res. Vol.63 , No.7,pp. 1449–1453.
[25]. Friedenson B (2010). “A Theory that Explains the Tissue Specificity of BRCA1/2 Related and Other Hereditary Cancers”. Journal of Medicine and Medical Sciences Vol. 1, No.8, 372–384.
[26]. Tonin, PN; Serova, O; Lenoir, G; Lynch, H; Durocher, F; Simard, J; Morgan, K; Narod, S. (1995). “BRCA1 Mutations in Ashkenazi Jewish Women”. American Journal of Human Genetics Vol.57, No. 1,p. 189.
[27]. Narod, SA; Foulkes, WD. (2004). “BRCA1 and BRCA2: 1994 and Beyond”. Nature Reviews on Cancer Vol.4, No.9,pp. 665–676.
[28]. Fesik SW, Shi Y. (2001). “Controlling the Caspases”. Science Vol.294,pp. 1477–1478.
[29]. Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB (2000). “Bcl-2 Inhibits Bax Translocation from Cytosol to Mitochondria during Drug-Induced Apoptosis of Human Tumor Cells”. Cell Death Differ. Vol., No.1,pp. 102–111.
[30]. Santos A. Susin; Daugas, E; Ravagnan, L; Samejima, K; Zamzami, N; Loeffler, M; Costantini, P; Ferri, KF et al. (2000). “Two Distinct Pathways Leading to Nuclear Apoptosis”. Journal of Experimental Medicine Vol.192, No. 4, pp. 571–580.
[31]. Zhou, G. P. & Doctor, K. (2003). “Subcellular Location Prediction of Apoptosis Proteins. PROTEINS”: Structure, Function, and Genetics No.50, pp. 44-48.
[32]. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S. “Isolation and Characterization of a Human p53 cDNA Clone: Expression of the Human P53 Gene”. EMBO J. Vol.3, No13.pp. 3257–3262.
[33]. May, P. and May, E. (1999). “Twenty Years of p53 Research: Structural and Functional Aspects of the p53 Protein”. Oncogene, No.18, pp. 7621–7636.
[34]. McBride OW, Merry D, Givol D (1986). “The Gene for Human p53 Cellular Tumor Antigen is Located on Chromosome 17 Short Arm (17p13)”. Proc. Natl. Acad. Sci. U.S.A. 83 (1): 130–134.
[35]. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM (1986). “Localization of gene for human p53 tumour antigen to band 17p13”. Nature 320 (6057): 84–85.
[36]. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). “p53 mutations in human cancers”. Science 253 (5015): 49–53
[37]. Koshland DE (1993). “Molecule of the Year”. Science Vol.262 , No.5142, P. 1953.
[38]. Thomas RK, et al. High-throuphut oncogene mutation profiling in human cancer. Nature Genetics. 2007; 39: 347-351.
[39].Weinstein IB, Joe AK.(2006).” Mechanisms of Disease”, Oncogene Addiction-Arationale for Molecular Targeting in Cancer Therapy. Nature Clinical Practice Oncology.No. 3, pp.448-457.
[40]. Wei Q, Lei L, Chen D. DNA Repair, Genetic Instability and cancer. World scientific. 2007; 270-014.
[41].Thompson CB.( 1995).” Apoptosis in the Pathogenesis and Treatment of Disease. Science.; 267(5203): 1456-62. Doi: 10. 1126/Science. 7878464. PMID 7878464.
[42].NagataS.Apoptosis DNA fragmentation. Exp. Cell Res. 2000, Vol. 256No.1,pp. 12-8. Doi: 10.1006/ excr. 4834. PMID 10739646.
[43]. Baak JP, Path FR, Hermsen MA, Meijer G, et al.( 2003).” Genomics and Proteomics in Cancer. Eur J Cancer. No. 39,pp. 1199-1215.
[44]. Scarpa A, Moore PS, Rigaud G, Meenestrina F.(2001).” Genetic in Primary Mediastinal B-cell lymphoma” An Updata. Leukemia & Lymphoma No. 41pp. 47-53.
[45]. Tachdjian G, Aboura A, Lapierre JM, Viguei F.( 2002).” Cytogenetic Analysis from DNA by Comparative Genomic Hybridization. Ann Genet,No.43,pp.147-154.
[46]. Kashiwagi H, Uchida K.( 2003).” Genome- Wide Profiling of Gene Amplification and Deletion in Cancer. Human Cell. No. 13,pp. 135-141.
[47]. Pollak JR, Perou CM, Alizadeh AA, Eisen MB, et al.(2003).” Genome-Wide Analysis of DNA Copy- Number Changes Using Cdna Microarrays. Nature Genet. No.23pp. 41-46.
[48].Albertson DG, Pinkel D.(2003).” Genomic Microarrays in Human Genetic Disease and Cancer”. Hum Mol Genet.,pp. 145-52.